FY2017 EPS Estimates for Resverlogix Corp. Increased by Zacks Investment Research (RVX)
Resverlogix Corp. (TSE:RVX) – Stock analysts at Zacks Investment Research raised their FY2017 earnings per share estimates for shares of Resverlogix Corp. in a research note issued to investors on Wednesday. Zacks Investment Research analyst J. Vandermosten now forecasts that the biotechnology company will post earnings of ($0.38) per share for the year, up from their prior forecast of ($0.51). Zacks Investment Research also issued estimates for Resverlogix Corp.’s Q4 2017 earnings at ($0.06) EPS, FY2018 earnings at ($0.26) EPS and FY2019 earnings at ($0.28) EPS.
Resverlogix Corp. (TSE RVX) opened at 1.39 on Friday. The firm has a 50-day moving average price of $1.94 and a 200-day moving average price of $1.95. Resverlogix Corp. has a one year low of $1.10 and a one year high of $2.47. The firm’s market cap is $146.63 million.
About Resverlogix Corp.
Resverlogix Corp. is a clinical-stage biotechnology company. The Company is a development-stage company, which is engaged in developing apabetalone (RVX-208), a first-in-class small molecule selective Bromodomain and ExtraTerminal domain (BET) inhibitor. Apabetalone is used for the treatment of patients with high-risk cardiovascular disease, (including peripheral arterial disease), diabetes mellitus, chronic kidney disease, Alzheimer’s disease and orphan diseases.
Receive News & Stock Ratings for Resverlogix Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix Corp. and related stocks with our FREE daily email newsletter.